Follistatin
Also known as FS344 · Follistatin 344
Myostatin/activin antagonist — human work is largely via gene therapy, not consumer peptide vials.
Extreme Risk
This substance is in the extreme platform risk category due to growth-factor signaling, mitogenic potential, or complete absence of human safety data. Exercise maximum caution.
Modality Mismatch
The legitimate clinical modality for this substance (e.g., gene therapy, recombinant protein infusion) is fundamentally different from consumer 'peptide vial' products. Consumer peptide versions may not deliver the same biological activity.
Evidence visual
Follistatin evidence and risk matrix
advanced researcher fit
Evidence
Tier C-D
Risk
extreme
Regulatory
not approved
WADA
unknown
FDA
unknown
Route
subcutaneous
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
Follistatin antagonizes myostatin and activin signaling, modulating muscle growth pathways. In legitimate clinical exploration, human work includes gene transfer approaches (e.g., AAV1.CMV.huFS344 protocols) — not comparable to consumer 'peptide vial' narratives. The gap between consumer marketing and legitimate clinical modality is large. Systemic muscle-growth modulation carries theoretical off-target risks; treat as extreme risk.
Decision path
Where Follistatin fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Follistatin belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Antagonizes myostatin and activin signaling, modulating muscle growth pathways.
subcutaneous
Gene therapy: vector genome dosing (not comparable to consumer peptide vials).
Myostatin inhibition / muscle growth narrative. Legitimate modality is gene therapy, not RUO peptide.
Gene therapy effects measured over months. Consumer peptide timelines are speculative.
No consumer-grade data.
Systemic muscle-growth modulation carries theoretical off-target risks; extreme risk.
Unknown; likely interacts with anabolic pathways and endocrine status.
Cost at a glance
No reliable cycle cost estimate yet. We need cleaner listing price and pack-size data before showing a trustworthy number.
Known Interactions
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Follistatin.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.